6 results about "Acetazolamide" patented technology

Compositions including Δ-9-tetrahydrocannabinol (THC) and a carbonic andydrase inhibitor and methods of using these compositions for the treatment of obstructive sleep apnoea (OSA). The treatment method also includes administering dronabinol and acetazolaminde and combinations thereof to a subject in need thereof.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to phenyl sulfanilamide para-triazole derivatives, a preparation method and application of the phenyl sulfanilamide para-triazole derivatives in resisting carbonic anhydrase. The structural general formula of the derivative is as shown in formula I, the invention provides a brand-new phenyl sulfanilamide para-triazole derivative and pharmaceutically acceptable salt, the inhibition activity of the derivative on human carbonic anhydrase is obviously superior to that of traditional inhibitors acetazolamide and methazolamide, and the derivative has selective binding capacity on different human carbonic anhydrase subtypes and has the potential to be developed into a novel carbonic anhydrase inhibition drug.

A method for quantitative measurement of cerebral vascular reactivity (CVR) combines sequential gas delivery with ΔR2*-based perfusion analysis. Sequential gas delivery imposes a first stepwise reoxygenation after a first hypoxic condition and a second stepwise reoxygenation after a second hypoxic condition. In one mode, the second hypoxic condition produces greater vasodilation than the first; in another mode both hypoxia levels are minimal and an independent vasoactive stimulus, such as hypercapnia or acetazolamide, is applied between reoxygenations. MRI gradient-echo imaging records the ΔR2* time course in a target voxel during each reoxygenation. Sigmoid fitting yields perfusion metrics including relative cerebral blood flow, relative cerebral blood volume and mean transit time. Comparison of the metrics derived from the two reoxygenations provides a numerical CVR value that can be reproduced across sessions and subjects.

The application provides a PET imaging agent targeting a CAIX receptor, a PET imaging agent labeling precursor and a preparation method and application thereof, and belongs to the field of radiopharmaceutical labeling, wherein the PET imaging agent precursor has a structure as shown in formula I, formula II or formula III. The PET imaging agent and the PET imaging agent labeling precursor have the advantages of simple preparation method, short preparation time, high radiochemical yield, good in-vivo and in-vitro stability, high specificity, high uptake and the like, and can accurately and stably detect and locate a tumor or an inflammation site. In addition, the PET imaging agent is a Ga-68 labeled targeting CAIX radioactive probe synthesized based on the chemical structure of acetazolamide, the application can realize qualitative diagnosis of CAIX in a tumor, and can provide reliable basis for accurate diagnosis and correct decision in the stages of clinical staging, treatment decision, efficacy monitoring and the like, and finally realizes precise diagnosis and treatment.

A method for the quantitative measurement of cerebral vascular reactivity (CVR) combines sequential gas delivery with ΔR2*-based perfusion analysis. The sequential gas delivery induces a first stepwise reoxygenation following an initial hypoxic state and a second stepwise reoxygenation following a second hypoxic state. In one mode, the second hypoxic state produces greater vasodilation than the first; in another mode, both hypoxia levels are minimal, and an independent vasoactive stimulus, such as hypercapnia or acetazolamide, is applied between reoxygenations. MRI gradient echo imaging records the ΔR2* time course in a target voxel during each reoxygenation. Sigmoid fitting provides perfusion metrics, including relative cerebral blood flow, relative cerebral blood volume, and mean transit time.The comparison of the measured values ​​derived from the two reoxygenations yields a numerical CVR value that is reproducible across sessions and subjects.

The present application relates to a kind of drug for treating Meniere's disease and its application, it includes active ingredient ebselen and acetazolamide, wherein the weight ratio of ebselen and acetazolamide is 8-12:1.The present application can effectively improve the treatment or relieve Meniere's disease by using acetazolamide and ebselen in a certain proportion, by synergism, especially, can simultaneously relieve the rotation caused by Meniere's disease, nystagmus and head left and right swing.